瑞舒伐他汀对慢性心力衰竭患者细胞因子及心功能的影响被引量：39

下载PDF

导出

摘要目的研究瑞舒伐他汀对慢性心力衰竭患者血清细胞因子水平及心功能的影响,探讨他汀类药物应用于慢性心力衰竭患者的可行性。方法将73例慢性心力衰竭患者随机分为治疗组36例,对照组37例。两组均进行强心、利尿、扩血管、抗血小板聚集、抗心肌重构、营养心肌治疗。治疗组加瑞舒伐他汀10 mg.d-1,po。疗程6个月。于用药前及用药6个月结束时测定血清肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、血清超敏C-反应蛋白(hs-CRP)、血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、三酰甘油(TG)、红细胞沉降率(ESR)等的变化;通过超声心动图评价左心室舒张末期内径(LVEDD)、短轴缩短率(FS)、左心室舒张末期容积(LVEDV)、左心室收缩末期容积(LVESV)及射血分数(EF)。结果治疗组治疗后TNF-α为(3.1±1.2)ng.L-1、IL-6(5.2±3.1)ng.L-1、hs-CRP(18.2±7.4)mg.L-1、TC(3.24±0.47)mmol.L-1、LDL-C(2.03±0.51)mmol.L-1,对照组TNF-α为(4.9±1.6)ng.L-1、IL-6(9.8±5.2)ng.L-1、hs-CRP(36.6±14.4)mg.L-1、TC(5.37±0.83)mmol.L-1、LDL-C(3.53±0.89)mmol.L-1,治疗组较对照组明显降低(P<0.01),LVESV(162.84±30.13)较对照组(180.07±29.71)降低(P<0.05);治疗组FS(15.82±3.51)%,EF(30.23±5.35)%,对照组FS(11.92±3.22)%、EF(26.76±4.63)%,治疗组较对照组明显增高(P<0.01);两组治疗后ESR、HDL-C、TG、LVEDD、LVEDV比较差异无统计学意义。结论应用瑞舒伐他汀可以改善慢性心力衰竭患者的心功能,降低血清炎性细胞因子和炎症标志物的水平。瑞舒伐他汀很可能成为治疗慢性心力衰竭的有效药物。

作者骆高江姜昌浩陈智理龚心琰

机构地区浙江省义乌市中心医院心内科

出处《医药导报》 CAS 北大核心 2013年第1期44-47,共4页 Herald of Medicine

关键词瑞舒伐他汀心力衰竭慢性细胞因子

分类号 R972.6 [医药卫生—药品] R541.6 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献14

1BRAUNWALD E, BRISTOW M R. Congestive heart failure: fifty years of progress [ J ]. Circulation, 2000,102 (20) : 14- 23.
2CONRAADS V M, BOSMANS J M,SCHUERWEGH A L,et al. Effect of shortterm treatment with pravastatin on cytokines and cytokine receptors in patients with chronic heart failure due to ischemic and nonischemic disease[ J]. J Heart Lung Transplant ,2005,24 ( 8 ) : 1114-1117.
3汪明灯,高修仁.炎症细胞因子与慢性心力衰竭[J].新医学,2006,37(3):200-202. 被引量：34
4TORRE-AMIONE G. INMUNE activation in chronic heart failure[J]. Am J Cardiol,2005,95(llA) :3-8.
5RODRIGUEZ-REYN5 T S, ARRIETA O, CASTILLOMA- RTINEZ L, et al. Tumour necrosis factor alpha and troponin T as a predictor of poor prognosis in patients with stable heart failure [ J ]. Clin Invest Med, 2005,28 ( 1 ) : 23-29.
6YIN W H, CHEN J W, JEN H L, et al. Independent pro- gnostic value of elevated high-sensitivity C-reactive protein in chronic heart failure [ J ]. Am Heart J, 2004,147 ( 5 ) : 931-938.
7MANN D L,MCMURRAY J L, PACKER M,et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized eanercept worldwide evaluation (RENEWAL) [ J]. Circulation, 2004, 109 ( 13 ) : 1594 - 1602.
8SUGISHITA K, KINUGAWA K, SHIMIZU T, et al. Cellular basis for the acute inhibitory effects of IL-6 and TNF-alpha on excitation-contraction coupling [ J ]. J Mol Cell Cardiol, 1999,31 (8) : 1457-1467.
9TATARU M C, I-IEINRICH J, JUNKER R, et al. C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris [ J ]. Eur Heart J,2000,21(12) :1000-1008.
10AIKAWA M, RABKIN E, SUGIYAMA S, et al. An HMG- CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro[ J]. Circulation,2001,103 (2) :276-283.

二级参考文献51

1HIGUCHI Y,MCTIERNAN C F,FRYE C B,et al.Tumor necrosis factor receptors 1 and 2 differentially regulate survival,cardiac dysfunction,and remodeling in transgenic mice with tumor necrosis factor-alpha induced cardiomyopathy [J].Circulation,2004,109 (15):1892-1897.
2TSUTAMOTO T,WADA A,OHNISHI M T,et al.Transcardiac increase in tumor necrosis factor-alpha and left ventricular end-diastolic volume in patients with dilated cardiomyopathy [ J ].Eur J Heart Fail,2004,6(2):173-180.
3GAO C Q,SAWICKI G,SUAREZ-PINZON W L,et al.Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction[J].Cardiovasc Res,2003,57 (2):426-433.
4SETSUTA K,SEINO Y,OGAWA T,et al.Ongoing myocardial damage in chronic heart failure is related to activated tumor necrosis factor and Fas/ Fas ligand system [J].Jpn Circ J,2004,68 (8):747-750.
5DESWAL A,BOZKURT B,SETA Y,et al.Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel,etanercept) in patients with advanced heart failure [ J].Circulation,1999,99 (25):3224-3226.
6MANN D L,MCMURRAY J J,PACKER M,et al.Targeted anticytokine therapy in patients with chronic heart failure:results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) [ J ].Circulation,2004,109 (13):1594-1602.
7CHUNG E S,PACKER M,LO K H,et al.Randomized,double-blind,placebo-controlled,pilot trial of infliximab,a chimeric monoclonal antibody to tumor necrosis factor-alpha,in patients with moderate-to-severe heart failure:results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACHF) trial [J].Circulation,2003,107 (25):3133-3140.
8KREYDIYYEH S I,ABOU-CHAHINE C,HILAL-DANDAN R.Interleukin-1 beta inhibits Na^+-K^+ATPase activity and protein expression in cardiac myocytes [J].Cytokine,2004,26 (1):1-8.
9KANDA T,TAKAHASHI T.Interleukin-6 and cardiovascular diseases[J].Jpn Heart J,2004,45 (2):183-193.
10TANAKA T,KANDA T,TAKAHASHI T,et al.Interleukin-6-induced reciprocal expression of SERCA and natriuretic peptides mRNA in cultured rat ventricular myocytes [J].J Int Med Res,2004,32 (1):57-61.